ASCO GUIDELINES Bundle

Axilla Management in Early-Stage Breast Cancer

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475445

Contents of this Issue

Navigation

Page 3 of 11

4 Management Qualifying Statements for Further Axillary Treatment: SLN(-) Surgical Interventions • SLNB is currently the standard of practice for this population. • The evidence regarding the omission of ALND upon which this recommendation is based did not include patients who: ▶ had a history of another cancer ▶ had a multicentric breast cancer ▶ had a prior ipsilateral breast cancer surgery or prior ipsilateral axillary surgery ▶ were <18 or >80 years of age ▶ were pregnant or lactating ▶ were allergic to blue dye or radioisotope ▶ had evidence of metastatic disease ▶ had tumors >3 cm in diameter ▶ suffered from chronic life-threatening diseases possibly preventing the use of adjuvant therapy ▶ had stage T0 tumors (i.e., ductal carcinoma in situ [DCIS]), had multifocal tumors, and received previous neoadjuvant chemotherapy (NAC) For these patients, decisions regarding ALND should be made after discussion between patient and clinicians on a case-by-case basis, depending on the invasive component of the lesion, other clinical circumstances, and patient preferences. Radiotherapy Interventions • Patients with centrally or medially located tumors may modestly benefit (<5% difference) from LRNI compared with whole-breast irradiation (WBI) only (post-lumpectomy) or no post-operative radiation (post-mastectomy) in terms of disease-free survival (DFS), distant DFS, and loco-regional relapse, but not in terms of overall survival (OS). • Post-mastectomy patients with node-negative, triple-negative breast cancer who receive chemotherapy may benefit from chest wall radiotherapy compared with no radiotherapy in DFS and OS. • A radiotherapy dose fractionation schedule of 50 Gy in 25 fractions over five weeks is the current standard used in the relevant clinical trials. However, we recognize that there are other regimens now considered clinically appropriate and/or equivalent to this traditional fractionation.

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Axilla Management in Early-Stage Breast Cancer